CXCR2 and neoplasm: When Cxcr1/Cxcr2 were antagonized in Braf/Pten mice and tumorigenic melanoma cell lines via treatment with SX-682, similar alterations in tumor growth and the gene expression profiles were achieved, and this was accompanied by development of anti-tumor immune microenvironment.